Andrew S. Feigin, MD

Associate Professor, Feinstein Center for Neuroscience, The Feinstein Institute for Medical Research

Director, Laboratory of Experimental Therapeutics for Movement Disorders,
The Feinstein Institute for Medical Research

Director, Huntington’s Disease Society of America Center of Excellence, North Shore University Hospital

Professor, Neurology and Molecular Medicine, Hofstra Northwell School of Medicine

Phone: (516) 562-2410

About the Investigator

Dr. Feigin is the director of Experimental Therapeutics for Movement Disorders at the Feinstein Institute and director of the Huntington’s Disease Society of America Center of Excellence at North Shore University Hospital. He has been involved in clinical research for 18 years and has been a site principal investigator on more than 30 National Institute of Health and industry-sponsored clinical trials of new treatments for Parkinson’s disease and Huntington’s disease.

Since 2002, Dr. Feigin’s laboratory has been one of two centers in the New York metropolitan area (out of 50 nationwide) participating in the NIH Exploratory Trials in Parkinson’s Disease (NET-PD; U10 NS044484), which is an ongoing series of clinical research studies to identify disease modifying therapies for PD. More than 50 PD subjects have been enrolled in these trials. Dr. Feigin is also the Clinical Core Leader and Team Leader (Project 3) of the Morris K. Udall Center of Excellence in Parkinson’s Disease Research at The Feinstein Institute for Medical Research.

Research Focus

Dr. Feigin’s research focuses on using state-of-the-art PET imaging methods to elucidate the mechanisms underlying current therapies for Parkinson’s disease. This work has led to the use of imaging in studies of novel therapies (e.g. gene therapy for PD). Dr. Feigin is interested in utilizing imaging as a biomarker for neurodegenerative disorders in the preclinical phase of illness. In addition to his research interests, Dr. Feigin remains a committed and busy clinician caring for patients with PD and related movement disorders.

The Experimental Therapeutics for Movement Disorders division within the Center for Neurosciences conducts clinical trials of new therapies for Parkinson’s disease (PD), Huntington’s disease, and other Movement Disorders. The division has conducted single site clinical trials of novel therapies early in clinical development (e.g. gene therapy for PD), and has participated in more than 30 multicenter clinical trials. These trials have been funded both by the pharmaceutical industry and by the National Institutes of Health. This division has been a part of the NIH initiative to identify disease modifying therapies for PD (the NET-PD trials) since its inception more than 10 years ago, and is a participating site in the new NIH clinical trials initiative NeuroNEXT (Network for Excellence in Neuroscience Clinical Trials).

Lab Members

Barbara Shannon, RN
Phone: (516) 562-2905

Jean Ayan, RN
Phone: (516) 562-2426


Swarthmore College, PA
Degree: B.A.
Field of Study: Biology

Columbia University, NY
Degree: M.D.
Field of Study: Medicine

Awards & Honors

1988 Dean’s Day Award for medical student research, Columbia University College of Physicians and Surgeons, New York, NY
1997 Junior Faculty Fellowship Award of the Parkinson Disease Foundation
2000 Director, Huntington’s Disease Society of America, Center of Excellence at North Shore University Hospital, Manhasset, NY
2002 F01 (20) Fellowship Study Section in Brain Disorders and Clinical Neuroscience
2003 Elected to the American Neurological Association
2006 The Best Abstract on Parkinson’s Disease, 20th Annual Symposia on Etiology, Pathogenesis and Treatment of Parkinson’s Disease and Other Movement Disorders, Chicago, IL

  1. Lewitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A (Corresponding author). “AAV2-GAD gene therapy for advanced Parkinson’s disease: a double-blind, sham-surgery controlled, randomized trial.” Lancet Neurol 2011; 10(4):309-19.2)
  2. Pourfar M, Feigin A (Shared first and corresponding author), Tang C, Carbon-Correll M, Bussa M , Budman C, Dhawan V, Eidelberg D. “Abnormal Metabolic Brain Networks in Tourette Syndrome.” Neurol 2011; 76:944-952.
  3. Feigin A. “Pridopidine in treatment of Huntington’s disease: beyond chorea?” Lancet Neurol 2011; 10(12): 1036 – 1037.
  4. Feigin A. “Commentary in Parkinson’s Disease Monitor and Commentary.” 2009; 2(4): 3.
  5. Niethammer M, Feigin A. “Imaging Applications to Parkinson’s Disease Clinical Trials. In: Imaging in Parkinson’s Disease.” D Eidelberg, editor. Oxford University Press, 2011: 181-190.
  6. Niethammer M, Feigin A, Eidelberg D. “Functional neuroimaging in Parkinson’s disease.” Cold Spring Harb Perspect Med. 2012; 2(5):a009274.
  7. Tang C, Feigin A. “Monitoring Huntington’s disease progression through preclinical and early stages.” Neurodegenerative Disease Management. 2012: 2(4):421-435.
  8. Kaplitt MG, Feigin A (Shared first author), Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ. “Safety and Tolerability of AAV-GAD Gene Therapy for Parkinson’s Disease: An open label, phase I trial.” Lancet 2007; 369(9579):2097-105.
  9. Feigin A, Kaplitt MG, Tang C, Lin T, Mattis P, Dhawan V, During MJ, and Eidelberg D. “Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson’s disease.” Proc Nat Acad Sci 2007; 104(49):19559-19564. [PMCID: PMC2148328]
  10. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D. “Thalamic metabolism and symptom onset in preclinical Huntington’s disease.” Brain 2007; 130(Pt 11):2858-67.

View more at PubMed